{"id":"W2056348171","doi":"10.1016/j.cgh.2011.04.031","title":"Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial","year":2011,"lang":"en","type":"article","venue":"Clinical Gastroenterology and Hepatology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":170,"is_retracted":false,"has_abstract":false,"ca_institutions":"Robarts Clinical Trials","funders":"UCB Pharma","keywords":"Certolizumab pegol; Medicine; Placebo; Internal medicine; Clinical endpoint; Adverse effect; Randomized controlled trial; Clinical trial; Gastroenterology; Maintenance therapy; Surgery; Tumor necrosis factor alpha; Infliximab; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002727116,0.002489039,0.007108433,0.0007113757,0.0007802548,0.001676592,0.001217751,0.004090721,0.009717443],"category_scores_gemma":[0.003050225,0.001208495,0.003288256,0.0006789769,0.002435711,0.002130892,0.0007219896,0.003960769,0.001503194],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008346981,"about_ca_system_score_gemma":0.001021952,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001017346,"about_ca_topic_score_gemma":0.001517228,"domain_scores_codex":[0.9986899,0.0006724285,0.0001073064,0.0002530098,0.00008354302,0.0001937492],"domain_scores_gemma":[0.9985952,0.0005542575,0.0002747012,0.000121583,0.00009147906,0.0003628475],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9930537,0.0009647437,0.0001915324,0.0006426205,0.0008982436,0.00002780354,0.00001936465,0.0000771686,0.000546036,0.00006103584,0.0002423012,0.003275349],"study_design_scores_gemma":[0.9921394,0.00676939,0.000299298,0.00002136867,0.0004285947,0.000009261509,0.000009291242,0.00006692636,0.00004816596,0.00005870147,0.0001444715,0.000005115042],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9447604,0.03138271,0.002242381,0.003635337,0.003544341,0.008064107,0.002101857,0.000293392,0.003975465],"genre_scores_gemma":[0.9721178,0.009850707,0.002275247,0.003165076,0.001590324,0.004926091,0.001413525,0.00004471159,0.004616577],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009717443,"threshold_uncertainty_score":0.03250808,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02949072393060239,"score_gpt":0.3090283153474281,"score_spread":0.2795375914168257,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}